key: cord-0302438-68meganp
authors: Tiller, J. M.; Keogh, L.; McInerney-Leo, A.; Belcher, A.; Barlow-Stewart, K.; Boughtwood, T.; Gleeson, P.; Dowling, G.; Prince, A.; Bombard, Y.; Joly, Y.; Delatycki, M.; Winship, I.; Otlowski, M.; Lacaze, P.
title: A step forward, but still inadequate: Australian health professionals' views on the genetics and life insurance moratorium
date: 2021-05-29
journal: nan
DOI: 10.1101/2021.05.25.21257683
sha: 4906b2bf37a54dcdd01b654d681e6b6b84ba4c87
doc_id: 302438
cord_uid: 68meganp

Background In 2019, the Australian life insurance industry introduced a partial moratorium (ban) limiting the use of genetic test results in life insurance underwriting. The moratorium is industry self-regulated and applies only to policies below certain financial limits (eg AUD$500,000 of life cover). Methods We surveyed Australian health professionals (HPs) who discuss genetic testing with patients, to assess knowledge of the moratorium; reported patient experiences since its commencement; and HP views regarding regulation of genetic discrimination (GD) in Australia. Results Between April-June 2020, 166 eligible HPs responded to the online survey. Of these, 86% were aware of the moratorium, but <50% had attended related training/information sessions. Only 16% answered all knowledge questions correctly, yet 69% believed they had sufficient knowledge to advise patients. Genetics HPs' awareness and knowledge were better than non-genetics HPs' (p<0.05). There was some reported decrease in patients delaying/declining testing after the moratorium's introduction, however 42% of HPs disagreed that patients were more willing to have testing post-moratorium. Although many (76%) felt the moratorium resolved some GD concerns, most (88%) still have concerns, primarily around self-regulation, financial limits and the moratorium's temporary nature. Almost half (49%) of HPs reported being dissatisfied with the moratorium as a solution to GD. The majority (95%) felt government oversight is required, and 93% felt specific Australian legislation regarding GD is required. Conclusion While the current Australian moratorium is considered a step forward, most HPs believe it falls short of an adequate long-term regulatory solution to GD in life insurance.

Genetic discrimination (GD) is an area of international concern [1] [2] [3] [4] . In the context of life insurance, 73 GD can lead to increased premiums or denial of insurance applications. Predictive genetic testing 74 (where an individual has not developed disease but genetic testing can reveal a higher risk of 75 developing disease) can save lives due to preventative interventions or early treatment of disease. In 76

Australia and internationally, research shows that fear of insurance implications deters some at-risk 77 individuals from having clinically-indicated predictive genetic testing or participating in research[5- voluntarily introduced an industry self-regulated moratorium on the use of genetic test results by their 98 member organisations [15 16 ]. The FSC moratorium, which applies only to FSC member companies, 99 restricts insurers' access to and use of genetic test results for applications for life insurance cover for 100 or below AUD$500,000 only. Because travel insurance falls within general insurance, as distinct from 101 life insurance, it is not restricted by the moratorium and genetic test results can legally be used to 102 discriminate in underwriting, pursuant to s46 of the DDA. 103 104 As a self-regulated industry standard, the FSC moratorium is not legally binding or enforceable; nor is 105 it subject to government regulation or oversight. Legally, the insurance industry's right to use genetic 106 test results in underwriting in accordance with the DDA remains and is not affected by the 107 implementation of the FSC moratorium, which will be reviewed in 2022 and end in 2024, if not 108 renewed. The FSC have a Code of Practice, compliance with which is monitored by an external 109 committee of three persons including a consumer representative, an industry representative and an 110 independent chair [17] . At the time of publication, the FSC moratorium has not been incorporated into 111 the Code of Practice, although we understand that this is FSC's intention in future. 112 113 Health professionals (HPs) are key to ensuring that patients who are considering genetic testing are 114 adequately advised of the potential for life insurance discrimination before testing is undertaken. 115 Further, they often witness the deterrent effects of fears about life insurance implications, or hear 116 firsthand of GD experiences [18] . Australian correct answer (range 0-6). A mean knowledge score was calculated for comparison between groups. 177

The percentage of correct answers for each item was also calculated. Knowledge scores were 178 categorised into "good knowledge" (5-6 questions answered correctly), "average knowledge" (3-4 179 correct), and "poor knowledge" (0-2 correct). Z-tests were used to test for significance of differences 180 between groups, with p-values (2-sided) <0.05 considered significant. STATA 14 was used for 181 analysis [25] . Table 1 shows the characteristics of the surveyed population. The "Other" category under the 198 profession field is comprised of HPs representing more than 15 different fields, all of whom were 199 eligible for the study as they reported regularly discussing genetic testing with patients. These 200 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Table S1 ). These HPs are referred to as "non-genetics HPs", as distinguished from "genetics HPs" 203 (genetic counsellors, clinical geneticists, and genetics fellows). properly advise clients. On the objective knowledge test, about half (49%) had good knowledge (5-6 217 questions answered correctly) (see Table S2 for question-specific data). More genetics HPs answered 218 questions correctly (mean 4.5/6) than non-genetics HPs (mean 3.1/6) (z=7.3; P<0.05). Of the 50 219 genetics HPs who answered two or more questions incorrectly (average/poor knowledge), about 220 three-quarters (n=38) felt they understood insurance implications for individuals undergoing genetic 221 testing extremely/reasonably well, and almost two-thirds (n=30) felt they had sufficient knowledge to 222 properly advise patients. However, of 25 non-genetics HPs who answered two/more incorrectly, only 223 a quarter felt they understood insurance implications extremely/reasonably well, (n=6) and a fifth 224 (n=5) felt they had sufficient knowledge. These differences between genetics and non-genetics HPs 225 were significant (z=4.3 (understanding) z=3.3 (knowledge), p<0.05). 226 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 29, 2021. ; https://doi.org/10.1101/2021.05.25.21257683 doi: medRxiv preprint Impact on practice and testing (Table 3 ) 228

HPs were asked in this survey about how often patients either delayed or declined having predictive 229 genetic testing due to life insurance concerns, both before the moratorium was introduced and then 230 after the moratorium was introduced (Fig 2A and 2B) . Overall, 63% of HPs said patients delayed testing 231 because of life insurance concerns often/sometimes before the moratorium, and 39% said they 232 delayed often/sometimes after the moratorium was introduced (z=4.15; p<0.05). Similarly, 39% said 233 patients refused testing due to life insurance concerns often/sometimes pre-moratorium, compared 234 with 18% post-moratorium (z=4.18; p<0.05). 235

Although the FSC moratorium does not apply to travel insurance, this can be a source of some 237 confusion for both patients and consumers. GD in travel insurance was raised as an issue by several 238

HPs in free-text responses (see below). When asked about how often patients delay or decline 239 predictive testing due to travel insurance concerns, 11% of HPs said patients delay often/sometimes, 240 and 12% said patients refuse often/sometimes. 241 242 Views on the FSC moratorium's effectiveness and regulation (Table 4 ) 243

Almost all HPs (93%) agreed/strongly agreed that "consumers are better protected post-moratorium 244 than they were before the moratorium was introduced". Although 76% felt the FSC moratorium 245 resolved some concerns the HPs had about insurance discrimination, 88% still had concerns about 246 insurance discrimination after its introduction. 247 248 Most HPs agreed/strongly agreed that the FSC moratorium is easy to understand (80%) and easy to 249 explain to patients (76%); however, a number (20% and 24% respectively), disagreed/strongly 250 disagreed, showing a portion of HPs find it difficult to understand and/or explain. HPs were split 251 almost evenly in their views regarding both questions "patients are less confused than they used to be 252 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2021. ; https://doi.org/10.1101/2021.05.25.21257683 doi: medRxiv preprint about insurance implications of genetic testing" (51% agreed/strongly agreed; 49% disagreed/strongly 253 disagreed) and "patients are more willing to have predictive genetic testing than they were before the 254 moratorium was introduced" (59% agreed/strongly agreed; 41% disagreed/strongly disagreed). 255

The vast majority (95%) of HPs (with no significant difference between genetics and non-genetics HPs 257 (z=0.2; p=0.83)) stated that a formal agreement between government and the life insurance industry 258 (as exists in the UK) is required in Australia ( Fig 2C) . This question allowed optional free text to allow 259 for HPs to elaborate on their answer (see Table S3 for all free-text responses grouped into categories). years' experience) stated, "Insurance companies currently load premiums or withhold cover on much 270 less scientific premises than genetic test results. By making these 'special' we do more harm than good 271 by making people afraid of genetic testing and complicating the process". 272

The vast majority (93%) of HPs also indicated that the Australian government should introduce 274 legislation to regulate the use of genetic test results in life insurance (no significant difference between 275 genetics/non-genetics HPs (z=-0.1; p=0.94)) ( Fig 2D) . Of 149 HPs, 15 elaborated (13 "yes"; 3 "no") 276 (Table S3) . Four HPs expressed mistrust of insurers, with Participant 207 (genetic counsellor, >20 277 years' experience) stating, "if it is not in law, why would an insurance company do it?". Four HPs 278 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2021. Thirteen percent (n=20) chose self-regulation by the FSC, though 7 of these also chose "legally 296 enforceable rules" indicating a preference for a blended regulatory approach. Forty-nine percent of 297 HPs felt either very or somewhat dissatisfied with the moratorium as a solution to GD in life insurance. 298

Only 4% felt "very satisfied". 299 300 Benefits and limitations of the moratorium (Table 5 ) 301

Sixty-two HPs responded to the optional free-text question "In your opinion, what, if any, are/have 302 been the benefits of the moratorium?" Table 5a sets out the categories of benefits that were 303 expressed, with example quotes (see Supplementary Table S4 for full responses). The most common 304 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2021. ; https://doi.org/10.1101/2021.05.25.21257683 doi: medRxiv preprint responses were "increased reassurance/patients more willing to have genetic testing" (34%) and 305 "some protection provided" (31%). Sixty-one HPs provided optional feedback to the question, "in your 306 opinion, what, if any, are the limitations of the moratorium?" (Table 5b, Table S4 ). The most commonly 307 raised limitations were "insurance companies' compliance/ self-regulation" (46%), "financial limits" 308 (44%), and "temporary nature of the moratorium" (31%). Similar issues arose in free-text comments 309 in the final question, "Do you have any final comments?" (Table S5) In this study, we surveyed Australian health professionals' (HPs) knowledge, experiences, and opinions 320 regarding the current industry self-regulated moratorium on genetic testing and life insurance. We 321 found that most HPs who discuss genetic testing with clients are aware of the FSC moratorium, though 322 knowledge of key aspects of the moratorium could be improved. Both awareness of and knowledge 323 about the moratorium are superior for genetics HPs than non-genetics HPs. Many HPs expressed a 324 view that the moratorium had resolved some of their concerns with GD. However, the majority of HPs 325 still have concerns regarding the potential for GD in life insurance and feel that the moratorium does 326 not adequately address those concerns. Most HPs feel that the moratorium does not represent an 327 adequate long-term regulatory solution for Australia. Specifically, the majority of HPs feel that more 328 stringent consumer protections are required, especially in the form of stronger government regulation 329 or legislation. Key findings of our study are summarized in Figure 3 . 330

In our previous survey of Australian genetics HPs, conducted before the FSC moratorium was 332 introduced[18], we found that only 9% (n=6/69) of HPs felt regulation at the time was adequate. 333

Now, after the introduction of the FSC moratorium, we still find that >90% believe government 334 regulation and legislation are required. Although the moratorium is seen as a step forward, most 335

Australian HPs remain concerned about the potential for GD, and its impact on patients. We found 336 evidence of recognition from HPs regarding improved consumer protections, compared with the pre-337 moratorium situation, with most HPs agreeing that consumers are better protected now, after the 338 introduction of the FSC moratorium. When asked about benefits of the moratorium, some HPs cited 339 increased willingness of patients to have genetic testing. However, despite some reported reduction 340 in patients delaying or refusing testing for insurance reasons, more than 40% of HPs still disagreed 341 that patients are more willing to have testing following the introduction of the FSC moratorium, 342

suggesting the desired impact of the moratorium has not been fully achieved. 343 344 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Almost all HPs surveyed believe that a formal agreement between government and industry is 367 required for Australia. Further, most HPs felt that any moratorium should be regulated through legally 368 enforceable rules from the Australian government, including specific legislation to regulate life 369 insurers' use of genetic test results. Our findings demonstrate that HPs who offer genetic testing to 370 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The demographics of HPs in this study are similar to those of our previous study [18] . However, the 383 current cohort is larger (n=166, compared with n=87 previously) and more diverse due to the 384 expanded recruitment strategy. This survey has highlighted the diversity of health professionals who 385 are discussing genetic testing with patients, in line with the mainstreaming of genetic testing noted 386 earlier. This has also captured, for the first time in Australia, the perceptions of these HPs on this issue. 387

Although there was consensus among most HPs from genetics and non-genetics backgrounds on key 389 issues, including regulation, there was also divergence between genetics and non-genetic HPs in some 390 areas. Areas of divergence include awareness of the FSC moratorium, with only about half of non-391 genetics HPs who discuss genetic testing with patients being aware of the moratorium. Our results in 392 this regard are consistent with other studies that report poor awareness or understanding of local 393 non-discrimination laws/policies by HPs [32-34]. However, given the importance of considering 394 insurance issues where relevant before deciding whether to have a genetic test, this lack of awareness 395 is somewhat concerning, and raises questions about dissemination and how to more effectively raise 396 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2021. ; https://doi.org/10.1101/2021.05.25.21257683 doi: medRxiv preprint awareness, particularly among non-genetics HPs. The numbers of genetics and genetics HPs who had 397 read either the CGE or FSC fact sheets indicate that these are a reasonable method of disseminating 398 information to genetics HPs but not so effective for non-genetics HPs. 399 400 Another area of distinction between genetics and non-genetics HPs was in objective knowledge. When 401 only considering genetic HPs, 81% felt they had sufficient knowledge of insurance implications to 402 properly advise patients, which has increased from our previous research (61%; n=53/87) [18] . 403 However, only a small fraction of both genetics and non-genetics HPs answered all 6 questions about 404 key aspects of the FSC moratorium correctly, and about half had average or poor knowledge. For non-405 genetics HPs, there was a reasonable match between subjective and objective lack of knowledge. This 406 is consistent with international studies of non-genetics HPs, which found a correlation between HPs' 407 subjective and objective knowledge levels regarding genetic non-discrimination regulations [35] and 408 genetics generally [36] . However, although genetics HPs were more knowledgeable than non-genetics 409 HPs, they appeared to overestimate their knowledge more than non-genetics HPs, indicating some 410 mismatch between subjective and objective knowledge. 411 412 An area of historical misinformation is that of the impact of GD on health insurance. In our previous 413 survey[18], 15% of HPs incorrectly stated that genetic information could be used for health insurance 414 policies in Australia. In the current survey, a similar number (17%) of genetics HPs still answered this 415 question incorrectly, as well as 50% of non-genetics HPs. The knowledge gap between genetic and 416 non-genetic HPs overall was sizable, highlighting the need to train a wider range of HPs with the 417 mainstreaming of genetic testing. Surprisingly, given the recent policy changes and need for 418 dissemination and education around these changes, similar numbers of genetics HPs reported 419 attending training in our previous survey (51%) as this survey (55%). Further, a smaller percentage of 420 genetics HPs reported having read the CGE fact sheet (68%) than previously reported (85%)[18]. This 421 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2021. ; https://doi.org/10.1101/2021.05.25.21257683 doi: medRxiv preprint may explain the knowledge gaps despite clinician confidence (HPs who feel they have sufficient 422 knowledge may be less likely to seek out additional resources). 423 424 A significant finding of the study is that many HPs (50%) believe the FSC moratorium applies to travel 425 insurance, or are unsure of its application. As discussed, travel insurers are not restricted by the 426 moratorium. Several HPs raised concerns about insurance implications for travel insurance in free-text 427 comments regarding limitations of the moratorium and in the "final thoughts" section. This provides 428 further support for the contention that broader government regulation and oversight of the use of 429 genetic test results in insurance underwriting is required to adequately protect consumers. 430 431 Strengths of the current study include being the first of its kind to report HP views and experiences 432 since the introduction of the FSC moratorium. Also, to our knowledge, our study provides the first 433 example of a survey of HPs conducted both before and after the introduction of a major policy change 434 regarding GD and life insurance. By asking similar questions as our previous (pre-moratorium) survey, 435

we were able to undertake comparative analysis pre-and post-moratorium. Our survey reached a 436 wide range of HPs, covering traditional genetics HPs as well as other clinicians who discuss genetic 437 testing with patients. 438 439 Limitations of our study include the relatively small number of non-genetics HPs surveyed, which may 440 limit the generalisability to this group. HPs were asked some questions about patient experiences, 441 which is arguably second-hand information. Other studies, which will seek firsthand 442 experiences/perceptions of patients and consumers, are being developed as part of the A-GLIMMER 443 Project[37] to address this limitation. Given the rising prominence of the issue of life insurance 444 discrimination in Australia, response bias is a potential limitation. We attempted to address this by 445 making it an option for HPs to remain anonymous if they preferred. Further, views expressed by HPs 446 who were happy to be contacted (~20% of HPs) will be explored further through qualitative interviews, 447 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2021.

in a subsequent study. Our survey was conducted less than a year after the introduction of the FSC 448 moratorium (9 months). Although this was intentional to ensure data collection and analysis could 449 take place to inform the review of the moratorium, waiting longer could have resulted in different 450 responses and experiences from HPs. As the survey was conducted online and in early 2020, it is not 451 expected that COVID restrictions significantly affected participation. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2021. The Explanatory Statement provided to participants includes the following statement: "Participation 502 is completely voluntary and you are able to withdraw at any time. However, if you chose to remain 503 anonymous in completing the survey, we will not be able to identify your data in order to exclude it 504 from analysis." 505 506

The first question of the online survey completed by participants (following the reading of the 507 Explanatory Statement) was as follows: 508

"By continuing with this survey, you give your consent to being a participant in this research project 509

• Continue with survey 510

• I do not want to continue with this survey" (survey ended if this response was selected) 511 512

The Explanatory Statement provided to participants includes the following statement: "The data 514 collected will be de-identified so that the source of each response is not known, and the de-identified 515 data will be analysed and submitted for publication in a peer-reviewed journal." 516 517 518 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 29, 2021. ; https://doi.org/10.1101/2021.05.25.21257683 doi: . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) (8) In your opinion, how should insurers' compliance with the moratorium on using genetic test results in life insurance be regulated? (n=149) * more than one option could be selected . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 29, 2021. ; It would be better if there was NO discrimination at all, that was made law and insurance companies held accountable (not self-regulated).

P129 (GC, 0-5 y)

It is self-regulated and not legally enforceable, so only as good as the trust in the industry generally P89 (GC, 0-5 y)

Financial limits 28 (44%)

The limit on cover is relatively low. Despite industry assurance that most policies fall below this threshold a significant number of patients see this as limiting P229 (CG 15-20 y)

The amounts are too low and won't give enough reassurance to some.

P135 (CG >20 y) Temporary nature of moratorium

The uncertainty about how long it will be in place -we need this to be PERMANENT to enable patients not to fear having genetic testing because of insurance concerns as genetic testing can really influence their physical AND psychological health

The uncertainty of how this will apply in the future if someone wants to take out a policy in a few years and the moratorium no longer applies. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 29, 2021. ; https://doi.org/10.1101/2021.05.25.21257683 doi: medRxiv preprint

Establishing the International Genetic Discrimination Observatory

Looking Beyond GINA: Policy Approaches to Address Genetic 523

Comparative Approaches to Genetic Discrimination: Chasing 526 Shadows?

Should Australia Ban the Use of Genetic Test Results in Life 528 Insurance? Frontiers in Public Health

Choosing not to undergo predictive genetic testing for 531 hereditary colorectal cancer syndromes: expanding our understanding of decliners and 532 declining

Life insurance and genetic test results: a mutation carrier's fight to achieve 534 full cover

Is uptake of genetic testing for colorectal cancer 536 influenced by knowledge of insurance implications?

Exploring the Potential Emotional and Behavioural Impact of 539

Providing Personalised Genomic Risk Information to the Public: A Focus Group Study

Genetic Discrimination, and Genomic Medicine

Australian Law Reform Commission. Essentially Yours: The Protection of Human Genetic 549 Information in Australia. Secondary Essentially Yours: The Protection of Human Genetic

Genetics and Insurance in Australia: Concerns around a Self-552 Regulated Industry

Final Report -Royal Commission into Misconduct in the Banking, Superannuation and 554 Financial Services Industry. Canberra, 2019. 555 14. Commonwealth of Australia. Parliamentary Joint Committee on Corporations and Financial 556 services -life insurance industry

Financial Services Council. FSC ANNOUNCES MORATORIUM ON GENETIC TESTS FOR LIFE 561 INSURANCE TO START

Genetics, insurance and professional practice: Survey of the 566 Australasian clinical genetics workforce

Banning Genetic Discrimination in Life Insurance -Time to Follow 593

HM Government and Association of British Insurers. Code on Genetic Testing and Insurance. 596 Secondary Code on Genetic Testing and

Differential use of available genetic tests among primary care 600 physicians in the United States: results of a national survey

Influence of genetic discrimination perceptions and 603 knowledge on cancer genetics referral practice among clinicians

Are pharmacists from the province of Quebec ready to 606 integrate pharmacogenetics into their practice

Family Physicians' Awareness and Knowledge of the 609 Genetic Information Non-Discrimination Act (GINA)

Non-genetic health professionals' attitude towards, knowledge 612 of and skills in discussing and ordering genetic testing for hereditary cancer

Study protocol: the Australian genetics and life 615 insurance moratorium -monitoring the effectiveness and response (A-GLIMMER) project. 616

P130 (GC, 6-10 y)"Step in the right direction"

It is a step in the right direction but insurance concerns are still present for many patients and providers P108 (GC, 0-5 y)